Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin Addition in Poorly Controlled Type 2 Diabetes
NCT06145360Phase 4Completed
- Sponsor
- SINA Health Education and Welfare Trust
- Start
- Dec 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by SINA Health Education and Welfare Trust. Started Dec 2023; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06145360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06145360.